niacinamide has been researched along with Carcinogenesis in 16 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy." | 9.19 | A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). ( Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q, 2014) |
| "Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC." | 5.46 | Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017) |
| "Aim of the study was to investigate efficacy and safety of sorafenib in patients with advanced lung adenocarcinoma after failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy." | 5.19 | A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). ( Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q, 2014) |
| "Nicotinamide metabolism is important in carcinogenesis." | 3.01 | Nicotinamide N-methyl transferase and cancer-associated thrombosis: insights to prevention and management. ( Ardakany, MR; Ebrahimi, S; Jabbari, P; Rezaei, N, 2023) |
| "Sorafenib is a small molecule multikinase inhibitor that acts against different cancer cell lines and is used for the treatment of HCC." | 1.46 | Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation. ( He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y, 2017) |
| "Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors." | 1.43 | (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016) |
| "Human hepatoma cells stably expressing short hairpin RNA targeting AR and cells over-expressing AR were generated." | 1.40 | Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis. ( Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O, 2014) |
| "Pediatric ependymomas are highly recurrent tumors resistant to conventional chemotherapy." | 1.40 | Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( Adamski, J; Agnihotri, S; Barszczyk, M; Buczkowicz, P; Castelo-Branco, P; Dirks, PB; Elizabeth, C; Golbourn, B; Hawkins, C; Li, XN; Luu, B; Mack, SC; Mangerel, J; Morrison, A; Nethery-Brokx, K; Pajovic, S; Ramaswamy, V; Remke, M; Rutka, JT; Tabori, U; Taylor, MD; Van Meter, T; Yu, M, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Hofer, SJ | 1 |
| Kroemer, G | 1 |
| Kepp, O | 1 |
| Jabbari, P | 1 |
| Ardakany, MR | 1 |
| Ebrahimi, S | 1 |
| Rezaei, N | 1 |
| DeWaal, D | 1 |
| Nogueira, V | 1 |
| Terry, AR | 1 |
| Patra, KC | 1 |
| Jeon, SM | 1 |
| Guzman, G | 1 |
| Au, J | 1 |
| Long, CP | 1 |
| Antoniewicz, MR | 1 |
| Hay, N | 1 |
| Minocha, R | 1 |
| Martin, AJ | 1 |
| Chen, AC | 2 |
| Scolyer, RA | 1 |
| Lyons, JG | 1 |
| McKenzie, CA | 1 |
| Madore, J | 1 |
| Halliday, GM | 1 |
| Damian, DL | 2 |
| Galbraith, AR | 1 |
| Seabloom, DE | 1 |
| Wuertz, BR | 1 |
| Antonides, JD | 1 |
| Steele, VE | 1 |
| Wattenberg, LW | 1 |
| Ondrey, FG | 1 |
| Zhou, Q | 1 |
| Zhou, CC | 1 |
| Chen, GY | 1 |
| Cheng, Y | 1 |
| Huang, C | 1 |
| Zhang, L | 2 |
| Xu, CR | 1 |
| Li, AW | 1 |
| Yan, HH | 1 |
| Su, J | 1 |
| Zhang, XC | 1 |
| Yang, JJ | 1 |
| Wu, YL | 1 |
| Jiang, X | 1 |
| Kanda, T | 1 |
| Nakamoto, S | 1 |
| Miyamura, T | 1 |
| Wu, S | 1 |
| Yokosuka, O | 1 |
| Barszczyk, M | 1 |
| Buczkowicz, P | 1 |
| Castelo-Branco, P | 1 |
| Mack, SC | 1 |
| Ramaswamy, V | 1 |
| Mangerel, J | 1 |
| Agnihotri, S | 1 |
| Remke, M | 1 |
| Golbourn, B | 1 |
| Pajovic, S | 1 |
| Elizabeth, C | 1 |
| Yu, M | 1 |
| Luu, B | 1 |
| Morrison, A | 1 |
| Adamski, J | 1 |
| Nethery-Brokx, K | 1 |
| Li, XN | 1 |
| Van Meter, T | 1 |
| Dirks, PB | 1 |
| Rutka, JT | 1 |
| Taylor, MD | 1 |
| Tabori, U | 1 |
| Hawkins, C | 1 |
| Tang, W | 1 |
| Xue, R | 1 |
| Weng, S | 1 |
| Wu, J | 1 |
| Fang, Y | 1 |
| Wang, Y | 1 |
| Ji, L | 1 |
| Hu, T | 1 |
| Liu, T | 1 |
| Huang, X | 1 |
| Chen, S | 1 |
| Shen, X | 1 |
| Zhang, S | 1 |
| Dong, L | 1 |
| Tiwari, P | 1 |
| Sahay, S | 1 |
| Pandey, M | 1 |
| Qadri, SS | 1 |
| Gupta, KP | 1 |
| Delire, B | 1 |
| Stärkel, P | 1 |
| Wu, G | 1 |
| Wilson, G | 1 |
| Zhou, G | 1 |
| Hebbard, L | 1 |
| George, J | 1 |
| Qiao, L | 1 |
| Schneider, TC | 1 |
| Kapiteijn, E | 1 |
| van Wezel, T | 1 |
| Smit, JWA | 1 |
| van der Hoeven, JJM | 1 |
| Morreau, H | 1 |
| Yan, Y | 1 |
| Wang, L | 1 |
| He, J | 1 |
| Liu, P | 1 |
| Lv, X | 1 |
| Zhang, Y | 2 |
| Xu, X | 1 |
| MATUYAMA, M | 1 |
| NAGAYO, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study of Sorafenib (BAY 43-9006®) in Patients With Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)Treatment[NCT00922584] | Phase 2 | 65 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for niacinamide and Carcinogenesis
| Article | Year |
|---|---|
Nicotinamide N-methyl transferase and cancer-associated thrombosis: insights to prevention and management.
Topics: Antineoplastic Agents; Carcinogenesis; Humans; Neoplasms; Niacinamide; Nicotinamide N-Methyltransfer | 2023 |
Nicotinamide and the skin.
Topics: Acne Vulgaris; Animals; Autoimmune Diseases; Carcinogenesis; Dermatitis, Atopic; Humans; Keratosis, | 2014 |
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; | 2015 |
2 trials available for niacinamide and Carcinogenesis
| Article | Year |
|---|---|
A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.
Topics: Carcinogenesis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cell Count; Humans; Incidence; Macr | 2019 |
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins | 2014 |
11 other studies available for niacinamide and Carcinogenesis
| Article | Year |
|---|---|
Autophagy-inducing nutritional interventions in experimental and clinical oncology.
Topics: Autophagy; Carcinogenesis; Humans; Medical Oncology; Methionine; Micronutrients; Neoplasms; Niacinam | 2022 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; | 2018 |
Chemoprevention of Lung Carcinogenesis by Dietary Nicotinamide and Inhaled Budesonide.
Topics: Administration, Inhalation; Animals; Anti-Inflammatory Agents; Apoptosis; Benzo(a)pyrene; Budesonide | 2019 |
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endopl | 2014 |
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.
Topics: Animals; Brain Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Child, Preschool; Co | 2014 |
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Human | 2015 |
Combinatorial chemopreventive effect of butyric acid, nicotinamide and calcium glucarate against the 7,12-dimethylbenz(a)anthracene induced mouse skin tumorigenesis attained by enhancing the induction of intrinsic apoptotic events.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Apoptosis; Apoptotic Protease-Ac | 2015 |
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separa | 2015 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati | 2016 |
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tum | 2017 |
The influence of nicotinamide and diphosphopyridine nucleotide on azo dye and methyl-cholanthrene carcinogenesis.
Topics: Animals; Azo Compounds; Benz(a)Anthracenes; Carcinogenesis; Coloring Agents; Methylcholanthrene; NAD | 1960 |